Multiple Sclerosis dataBase Independent predictors of time to relapse after CIS in high-risk patients Tim Spelman 1*, Claire Meyniel 1,2*, Maria Trojano. - ppt download
MUDr. Havrdová: Nová kritéria diagnostiky RS | RS kompas
Eva HAVRDOVA | Charles University in Prague, Prague | CUNI | Department of Neurology (2. LF) | Research profile
Eva HAVRDOVA | Charles University in Prague, Prague | CUNI | Department of Neurology (2. LF) | Research profile
New insights into the burden and costs of multiple sclerosis in Europe: Results of the Czech Republic - Eva Havrdova, Gisela Kobelt, Jenny Berg, Daniela Capsa, Mia Gannedahl, Tomáš Doležal, , The
Solen: On-line kurz pro praktické neurology 2/2022 - Léčba pacienta s RS v průběhu dekád života
New insights into the burden and costs of multiple sclerosis in Europe: Results of the Czech Republic - Eva Havrdova, Gisela Kobelt, Jenny Berg, Daniela Capsa, Mia Gannedahl, Tomáš Doležal, , The
Roztroušená skleróza: Helena jí trpí 20 let, přesto žije spokojený život | Blesk.cz
Untitled
Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis–related Hospitalizations_ Integrated Analysis of the Delayed
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis | NEJM
Multiple sclerosis today: Disease monitoring, biomarkers and family planning - touchNEUROLOGY
PDF) Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies
Industrial pharmaceutical drug research has done more for the health of people with MS than academic neurologists: Yes
PDF) Myxovirus Resistance Protein A mRNA Expression Kinetics in Multiple Sclerosis Patients Treated with IFNβ | Eva Havrdova - Academia.edu
Polska Platforma Medyczna Polish Platform of Medical Research https://ppm.edu.pl Repozytorium Śląskiego Uniwersytetu Medyczneg
Efficacy and Safety of Ozanimod in the Blinded Extension (120 weeks) of RADIANCE Part A, a Phase 2 Trial in Relapsing Multiple S
Eva HAVRDOVA | Charles University in Prague, Prague | CUNI | Department of Neurology (2. LF) | Research profile
Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate_ Experiences of an international
Disease-activity-free status in patients with relapsing–remitting multiple sclerosis treated with daclizumab high-yield proces
The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges - Angelo Ghezzi, Maria Pia Amato, Gilles Edan, Hans-Peter Hartung, Eva Kubala Havrdová, Ludwig Kappos, Xavier Montalban, Carlo Pozzilli,
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
Effects of High and Low Efficacy Therapy in Secondary Progressive Multiple Sclerosis
Nové informace ke Covid 19 a RS - prof. Havrdová | RS kompas
Treatment sequencing in multiple sclerosis: The benefits of disease-modifying therapies - touchNEUROLOGY
Eva K. Havrdová: Nové trendy v léčbě RS | RS kompas
